GCIA
BIOTU

Gabelli & Co Investment Advisers’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,400
Closed -$255K – 509
2021
Q3 		$255K Hold
25,400
– – 0.03% 306
2021
Q2 		$256K Hold
25,400
– – 0.03% 293
2021
Q1 		$251K Buy
+25,400
New +$261K 0.03% 299

Other funds holding BIOTU

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.72% 1-Year Est. Return
BCM
BCK Capital Management Stamford, Connecticut $23M AUM 32.69% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Gabelli & Co Investment Advisers's BIOTU Position: Q4 2021 in Review

Gabelli & Co Investment Advisers sold out of Biotech Acquisition Company Unit (BIOTU) in Q4 2021, closing a stake of 25,400 shares — an estimated $255K sold.

Gabelli & Co Investment Advisers first reported a position in BIOTU in Q1 2021 and held it in 3 quarters. The position peaked at $256K in Q2 2021. 15 funds tracked by Wall St. Rank hold BIOTU as of Q4 2021.

  • Gabelli & Co Investment Advisers reported no remaining Biotech Acquisition Company Unit position as of Q4 2021 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 25,400 Biotech Acquisition Company Unit shares in Q4 2021, an estimated $255K.
  • Gabelli & Co Investment Advisers first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 3 quarters.
  • Gabelli & Co Investment Advisers's Biotech Acquisition Company Unit position peaked at $256K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q4 2021.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2021, filed 11 Feb 2022.